Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
IHC - Paraffin, ICC, Immunofluorescence, Western blot, Flow Cytometry, ELISA
Human (tested or 100% immunogen sequence identity)
Protein A purified
IHC - Paraffin (1:50)
Western blot (1:1000)
Flow Cytometry (1:25)
Specificity and Use
PARP1 antibody was raised against synthetic peptide (KLH coupled) corresponding to C-terminal residues adjacent to Asp214 in human PARP.
Detects endogenous levels of the large fragment (89kD) of human PARP produced by caspase cleavage. Does not react with full length PARP.
Suitable for use in ELISA, Western Blot, Immunohistochemistry, Immunofluorescence and Flow Cytometry. Western Blot: 1:1000. Immunohistochemistry (Paraffin): 1:50. Immunocytochemistry (IF): 1:200. Flow Cytometry: 1:25.
10 mM HEPES, pH 7.5, 150 mM sodium chloride, 0.1 mg/ml BSA, 50% glycerol. No preservative added.
Long term: -20°C; Short term: +4°C. Avoid repeat freeze-thaw cycles.
Involved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This modification follows DNA damages and appears as an obligatory step in a detection/signaling pathway leading to the reparation of DNA strand breaks. Mediates the poly(ADP-ribosyl)ation of APLF and CHFR.